ANIP Q4 2017 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$47M+23.8% YoY

Gross Profit

$27M56.8% margin

Operating Income

$7M15.6% margin

Net Income

-$10M-20.4% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

-$34M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$412M

Total Liabilities

$237M

Stockholders' Equity

$175M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$38M	+23.8%
Gross Profit	$27M	$21M	+26.0%
Operating Income	$7M	$1M	+468.5%
Net Income	-$10M	-$1M	-791.6%

Revenue Segments

Unapproved Products

$7M100%